TALARIS THERAPEUTICS INC (TALS) Stock Price, Quote, News and Overview
NASDAQ:TALS - Nasdaq - US87410C1045 - Common Stock - Currency: USD
TALS Quote, Performance and Key Statistics
2.72
-0.02 (-0.73%)
The current stock price of TALS is 2.72 USD. In the past month the price decreased by -5.88%. In the past year, price increased by 91.55%.
TALS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About TALS
Company Profile
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company, which engages in the development of allogeneic hematopoietic stem cell transplantation. The company is headquartered in Louisville, Kentucky and currently employs 129 full-time employees. The company went IPO on 2021-05-07. The firm is engaged in developing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The firm is advancing a pipeline of programs across three therapeutic categories: solid organ transplantation, severe autoimmune disease, and severe non-malignant blood, immune and metabolic disorders. Its therapeutic approach, allo-HSCT therapy prevents organ rejection without the morbidity and mortality that has been associated with the use of anti-rejection medicines, also known as chronic immunosuppression. Allo-HSCT is used to replace diseased immune, blood or stem cells in patients with severe immune, blood or metabolic disorders. The Company’s lead product candidate, FCR001, which is central to its Facilitated Allo-HSCT Therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation.
Company Info
TALARIS THERAPEUTICS INC
570 Preston St., Suite 400
Louisville KENTUCKY US
CEO: Scott Requadt
Employees: 129
Company Website: https://talaristx.com/
Phone: 15023989250.0
TALARIS THERAPEUTICS INC / TALS FAQ
What is the stock price of TALARIS THERAPEUTICS INC today?
The current stock price of TALS is 2.72 USD. The price decreased by -0.73% in the last trading session.
What is the ticker symbol for TALARIS THERAPEUTICS INC stock?
The exchange symbol of TALARIS THERAPEUTICS INC is TALS and it is listed on the Nasdaq exchange.
On which exchange is TALS stock listed?
TALS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TALARIS THERAPEUTICS INC stock?
6 analysts have analysed TALS and the average price target is 20.4 USD. This implies a price increase of 650% is expected in the next year compared to the current price of 2.72. Check the TALARIS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TALARIS THERAPEUTICS INC worth?
TALARIS THERAPEUTICS INC (TALS) has a market capitalization of 116.44M USD. This makes TALS a Micro Cap stock.
How many employees does TALARIS THERAPEUTICS INC have?
TALARIS THERAPEUTICS INC (TALS) currently has 129 employees.
What are the support and resistance levels for TALARIS THERAPEUTICS INC (TALS) stock?
TALARIS THERAPEUTICS INC (TALS) has a support level at 2.69 and a resistance level at 2.94. Check the full technical report for a detailed analysis of TALS support and resistance levels.
Should I buy TALARIS THERAPEUTICS INC (TALS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TALS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TALS, evaluating the profitability, health, valuation and growth aspects
- TALARIS THERAPEUTICS INC (TALS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TALARIS THERAPEUTICS INC (TALS) Sales and EPS estimates to see what analysts future expectations are.
- TALARIS THERAPEUTICS INC (TALS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TALARIS THERAPEUTICS INC (TALS) Insider and Institutional Ownership to learn about the owners and their transactions.
- TALARIS THERAPEUTICS INC (TALS) Stock Chart to make your own analysis
- TALARIS THERAPEUTICS INC (TALS) Latest news and press-releases to stay up to date.
Does TALARIS THERAPEUTICS INC (TALS) stock pay dividends?
TALARIS THERAPEUTICS INC (TALS) has a dividend yield of 55.58%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of TALS dividend history, reliability and sustainability.
When does TALARIS THERAPEUTICS INC (TALS) report earnings?
TALARIS THERAPEUTICS INC (TALS) will report earnings on 2023-11-08, after the market close.
What is the Price/Earnings (PE) ratio of TALARIS THERAPEUTICS INC (TALS)?
TALARIS THERAPEUTICS INC (TALS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.79).
TALS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to TALS. When comparing the yearly performance of all stocks, TALS is one of the better performing stocks in the market, outperforming 97.24% of all stocks.
TALS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TALS. TALS has a great financial health rating, but its profitability evaluates not so good.
TALS Financial Highlights
Over the last trailing twelve months TALS reported a non-GAAP Earnings per Share(EPS) of -1.79. The EPS increased by 24.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.99% | ||
| ROE | -50.38% | ||
| Debt/Equity | 0 |
TALS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to TALS. The Buy consensus is the average rating of analysts ratings from 6 analysts.